News

What Does Danaher (DHR) FDA Clearance For AI AFib Detection Mean Now?

Danaher (NYSE:DHR) subsidiary Masimo received FDA clearance for AI-enabled atrial fibrillation detection in its Radius VSM wearable monitor. The approved system uses artificial intelligence to identify potential AFib episodes in patients using Masimo’s hospital-grade wireless device. The AFib detection feature is intended for use in acute care settings, adding a new digital monitoring function to Danaher’s diagnostics tools. Masimo’s new AI atrial fibrillation clearance matters, but...

Yahoo·16:13DHR

Danaher Posts First Earnings Under New CEO; Emphasizes Need For Improved Execution, Innovation

Danaher shares fell despite upbeat Q3 results. TD Cowen raised its target, citing tariffs and a cautious 2027 outlook.

Benzinga·12:06DHR

Citigroup Maintains Buy on Danaher, Raises Price Target to $270

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:DHR) with a Buy and raises the price target from $230 to $270.

Benzinga·11:12DHR

Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings

Danaher beat Q3 earnings and revenue estimates, raised FY2026 profit guidance, and analysts lifted price targets despite shares falling 1.8%.

Benzinga·11:07DHR

LH vs. DHR: Which Stock Is the Better Value Option?

LH vs. DHR: Which Stock Is the Better Value Option?

Yahoo·10:40DHR

Danaher (DHR) Q3 Earnings Fuel Stock Gains On Margin Expansion

Danaher came into this Q3 2026 report with the stock already grinding higher over the past three months. It then jumped another 4.3% to about $233.86 after the release. The move looks like a relief rally, yet the core story sits in the income statement. Management delivered roughly $6.6b of revenue and pushed adjusted operating margin to about 29%, while earnings per share over the trailing year reached just above $6. That combination of higher profitability and solid earnings power is what...

Yahoo·08:13DHR

Barclays Maintains Overweight on Danaher, Raises Price Target to $260

Barclays analyst Luke Sergott maintains Danaher (NYSE:DHR) with a Overweight and raises the price target from $255 to $260.

Benzinga·07:48DHR

JP Morgan Maintains Overweight on Danaher, Raises Price Target to $270

JP Morgan analyst Casey Woodring maintains Danaher (NYSE:DHR) with a Overweight and raises the price target from $250 to $270.

Benzinga·05:47DHR

TD Cowen Maintains Buy on Danaher, Raises Price Target to $270

TD Cowen analyst Dan Brennan maintains Danaher (NYSE:DHR) with a Buy and raises the price target from $255 to $270.

Stifel Maintains Buy on Danaher, Raises Price Target to $260

Stifel analyst Daniel Arias maintains Danaher (NYSE:DHR) with a Buy and raises the price target from $220 to $260.

Benzinga·04:48DHR

DHR Q3 deep dive: execution focus and AI strategy underpin improved outlook

Diversified science and technology company Danaher (NYSE:DHR) met Wall Street’s revenue expectations in Q3 2026, with sales up 8.3% year on year to $6.55 billion. Its non-GAAP profit of $2.11 per share was 10% above analysts’ consensus estimates.

Yahoo·04:14DHR

Baird Maintains Outperform on Danaher, Raises Price Target to $254

Baird analyst Catherine Schulte maintains Danaher (NYSE:DHR) with a Outperform and raises the price target from $246 to $254.

Benzinga·03:23DHR

Danaher (DHR) Stock Fair Value Edges Higher After Analysts Lift Targets

Danaher is back in focus as analysts edge price targets into the US$240 to US$255 range, with some models now centering around fair value of about US$244.14. This shift reflects recent research that is divided between optimism on improving demand in life science tools and diagnostics, and concern that current valuations may already factor in a recovery, especially around bioprocessing. In the sections that follow, you will see how these updated targets fit into the broader narrative and what...

Yahoo·00:26DHR

Why Danaher Stock Bounced Higher Today

The conglomerate posted its latest set of quarterly earnings that morning.

Yahoo·17:26DHR

Danaher Reports Third Quarter 2026 Results

Fintel·16:49DHR

Danaher: 3 Key Takeaways for Long-Term Investors

Portfolio reshaping complete, management now pivots to organic growth and disciplined acquisitions to compound returns.

Yahoo·14:40DHR

Danaher (DHR) Q3 2026 Earnings Call Transcript

Revenue beat $6.6B with 8.5% growth; free cash flow hit $1.6B for the quarter.

Yahoo·13:17DHR

Danaher Corporation Q3 2026 Earnings Call Summary

Moby summary of Danaher Corporation's Q3 2026 earnings call

Yahoo·12:57DHR

Danaher Jumps 4% on Q3 Beat: “Improving Trends” Across Its End Markets

Danaher (DHR:NYSE) shares were up about 4% on Wednesday (trading at about $233) after the life sciences company beat third-quarter profit estimates and raised its full-year earnings guide. The stock opened about 3% lower before buyers took over.

Yahoo·12:16DHR

Abbott to Separate Nutrition Business as Quarterly Results, Along With Thermo Fisher, Danaher Rise Annually

Abbott Laboratories (ABT) disclosed plans on Wednesday to separate its nutrition business into a pub

Yahoo·11:06DHR

Medical Giants Thermo Fisher, Danaher Reverse Higher — What Investors Are Seeing

Thermo Fisher and Danaher stocks reversed higher Wednesday after reporting third-quarter metrics and full-year guidance.

Yahoo·11:05DHR

Danaher Q3 Earnings Call Highlights

Danaher (NYSE:DHR) reported third-quarter 2026 results that exceeded its expectations, citing improved market conditions, commercial execution and operational performance across its Biotechnology, Life Sciences and Diagnostics businesses. Sales totaled $6.6 billion for the quarter. Core revenue gro

DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line

Danaher's third-quarter earnings beat estimates by 9.9%, driven by stronger Biotechnology profitability, while it raised its 2026 adjusted earnings outlook.

Yahoo·09:45DHR

Strong Price Rally Validates Danaher’s (DHR) Undervalued Entry Point in Core Diagnostics Engine

L1 Capital, an investment management firm, released its “L1 Capital International Fund” (unhedged) third-quarter 2026 investor letter. A copy of the letter can be downloaded here. This Quarterly Report covers the unusually complex investment environment, AI’s opportunities and challenges, portfolio strategy, September 2026 performance, and recent adjustments. The Fund returned +3.5% net of fees in […]

Yahoo·08:41DHR

Danaher shares rise in premarket trade as Q3 earnings beat estimates

Investing.com – Danaher Corporation (NYSE:DHR) shares rose in premarket trading on Wednesday after the life sciences and diagnostics company reported third-quarter adjusted earnings of $2.11 per share, beating analyst expectations of $1.92, while revenue climbed 8.5% year on year to $6.6 billion, topping estimates of $6.56 billion.

Yahoo·06:41DHR

Danaher (DHR) Tops Q3 Earnings and Revenue Estimates

Danaher (DHR) delivered earnings and revenue surprises of +9.90% and +0.10%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo·06:25DHR

Danaher: Q3 Earnings Snapshot

Danaher Q3 2026 Earnings Call Transcript

Danaher (NYSE:DHR) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For

Benzinga·05:13DHR

Global Nano Bioreactor Market Report 2026: Size, Share, Trends and Forecast to 2030 | Capitalize on 12% CAGR with Leading Players Thermo Fisher Scientific, Danaher, Lonza, Cytiva and Sartorius

Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Nano Bioreactor Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global nano bioreactor market is experiencing rapid growth, driven by expanding biotechnology research, increased adoption of microfluidic bioprocessing, and demand for highly controlled, small-scale cell culture systems. The market is projected to grow from $4.64 billion in 2025 to $5.21 billion in 2026, representing a compound annual growth rate (CAGR) of 12.3

Yahoo·04:04DHR

Danaher (DHR) Reports Q3: Everything You Need To Know Ahead Of Earnings

Diversified science and technology company Danaher (NYSE:DHR) will be announcing earnings results this Wednesday morning. Here’s what to expect.

Yahoo·04:13DHR

Danaher Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Danaher will report Q3 earnings Oct. 21, with estimates of $1.92 EPS and $6.56B revenue; shares fell 1.1% despite bullish analyst targets.

Benzinga·03:55DHR

Roper Technologies (ROP) vs. Danaher (DHR): Which Is the Better Long-Term Capital Allocator?

Roper Technologies, Inc. (NASDAQ:ROP) and Danaher Corporation (NYSE:DHR) have returned 4.01% and 18.97%, respectively, over the last six months, as of October 15. This compares to a 21.5% return for the Insider Monkey Billionaire Index and 15.74% for the State Street SPDR S&P 500 ETF Trust. Both have built their businesses around a similar idea: […]

Yahoo·10:48DHR

What Danaher Stock's AI Lab Push Means For Shareholders

Danaher recently announced a collaboration with NVIDIA to combine its instruments, automation and workflow software with NVIDIA’s accelerated computing and AI platforms, alongside plans for an AI-powered autonomous lab at Abcam focused on faster development of custom antibodies and molecular tools. This push into AI-enabled science and autonomous labs directly targets Danaher’s core operating model, tying future demand for consumables and instruments to more automated, data rich research...

Yahoo·05:13DHR

Danaher (DHR) Teams Up To Bring AI Into Scientific Research Workflows

Danaher (NYSE:DHR) announced a new collaboration with NVIDIA to apply AI and accelerated computing across its scientific tools and workflows. The partnership focuses on embedding NVIDIA AI platforms into research instrumentation to support automation and data rich experimental processes. This move extends Danaher's recent push into AI enabled science, following its autonomous lab initiative at Abcam. The NVIDIA collaboration on AI enabled research sits against broader themes our work on...

Yahoo·15:15DHR

Danaher’s Stock Is Pricing in a Recovery. Can Its Earnings Deliver?

Danaher Corporation (NYSE:DHR) has built its reputation on acquiring businesses with durable market positions and improving their performance through its Danaher Business System, a framework for operational efficiency and continuous improvement. That model has helped turn the company into a major player in diagnostics, biotechnology, and life-sciences tools. But with its underlying growth still relatively […]

Yahoo·12:18DHR

Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?

DHR's Q3 results are due Oct. 21, with growth in Biotechnology, Diagnostics and Life Sciences expected to boost revenues, while rising costs and currency headwinds weigh on earnings.

Yahoo·08:41DHR

Seeking Clues to Danaher (DHR) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Evaluate the expected performance of Danaher (DHR) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Yahoo·08:15DHR

Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?

Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Yahoo·11:10DHR

Danaher (DHR) Earnings Expected to Grow: Should You Buy?

Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo·09:00DHR

Danaher Teams Up With NVIDIA, Aims To Bring Accelerated Computing, Physical AI Into Labs

Danaher CEO Julie Sawyer Montgomery said AI is transforming science, emphasizing the collaboration’s vision for more connected, adaptive and accessible innovation.

Yahoo·06:57DHR

DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace?

Danaher's Biotechnology segment posts 4% sales growth, but tough comparisons and shipment timing could test its momentum.

Yahoo·09:31DHR

Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?

Gilead Sciences, Inc. (NASDAQ:GILD) and Danaher Corporation (NYSE:DHR) are both showing signs of stronger growth, but they are getting there in very different ways. Gilead already has momentum, which is supported by its HIV business that is expanding at a double-digit rate, with newer products contributing more and resulting in management raising its sales outlook. […]

Yahoo·14:45DHR

Danaher Isn't Anything Special, Even After Absorbing Masimo

Danaher (DHR) stays a hold: modest core growth and higher leverage after the Masimo acquisition limit upside despite synergies.

SeekingAlpha·22:49DHR

Danaher (DHR) Stock Looks Reasonable On Label Free Detection Growth

Danaher has delivered a 17.4% gain over the past year, which puts a spotlight on one core issue for anyone looking at the stock today: whether the current share price can be explained by the cash flows the business is expected to generate. The 17.4% 1 year return means recent buyers have seen a clear payoff, which raises the question of how much future cash generation is already reflected in the valuation. Recent reports on areas such as label free detection and single use bioreactors...

Yahoo·17:18DHR

Global Pharmaceutical Filtration Report: Biologics Manufacturing Shifts as Danaher, Merck KGaA, Sartorius, 3M and Thermo Fisher Reshape the Market

Biologics, stricter purity rules and flexible manufacturing are driving demand for single-use, automated and continuous filtration, advanced membranes and sustainable systems.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Pharmaceutical Filtration - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Pharmaceutical Filtration was estimated at US$8.0 Billion in 2025 and is projected to reach US$23.4 Billion by 2032, growing at a CAGR of 16.7% f

Yahoo·05:56DHR

Bioreactors Market Outlook 2026-2035 - Featuring Profiles of 3 Leading Companies: Sartorius, Thermo Fisher Scientific, and Danaher

Bioreactors Market Gains Momentum as Single-Use Systems, Automation and Advanced Therapies Reshape BiomanufacturingDublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Bioreactors Market Opportunity, Growth Drivers, Industry Trend Analysis and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Bioreactors Market to Reach USD 38.9 Billion by 2035 as Advanced Biomanufacturing Expands The global bioreactors market was valued at USD 13.8 billion in 2025 and is projected to reach

Yahoo·05:01

Danaher Schedules Third Quarter 2026 Earnings Conference Call

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.

Yahoo·16:15DHR

1 Mid-Cap Stock on Our Buy List and 2 We Avoid

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

Yahoo·10:08

Danaher (DHR) Could Be 8% Below Fair Value Following Its Dividend Reaffirmation

Danaher (DHR) has reaffirmed its shareholder payout, with the Board approving a regular quarterly cash dividend of $0.40 per share, payable on October 30, 2026, to holders of record on September 30. The reaffirmed dividend lands at a time when Danaher’s short-term momentum has picked up. The 90-day share price return is 17.78% and the 1-year total shareholder return is 10.73%, even though the 5-year total shareholder return is down 25.46%. Compare Danaher’s mix of dividend income and recent...

Yahoo·07:12DHR

Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key Players

The global point-of-care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at an 8.8% CAGR. Growth is driven by demand for rapid, accurate and decentralized testing, alongside advances in molecular diagnostics, microfluidics, multiplex assays and portable analyzers. Biochemistry holds the largest technology share, while molecular diagnostics and infectious disease testing are set for strong growth. Clinical laboratories lead by end user, and Nor

Yahoo·05:05

Danaher Announces Quarterly Dividend

Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 30, 2026 to holders of record on September 30, 2026.

Yahoo·16:15DHR

Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says

Thermo Fisher Scientific (TMO) and Danaher (DHR) are likely to return to mid-single-digit organic re

Yahoo·13:55DHR

ILMN Stock Keeps Climbing. Should You Climb On?

A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.

Yahoo·15:37

Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others

500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro

Yahoo·10:49DHR

Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation.

SeekingAlpha·02:17

Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.

Yahoo·08:49

Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share

The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher

Yahoo·06:48